Semax 'cope' claims vs. the actual nootropic evidence

What did @nocturnall.kent actually say?

The creator said semax "sucks asshole" because it "lacks any sort of potency" once it crosses the blood-brain barrier, despite looking promising on paper. They then pitched something called "atomax" as a more stable, more potent alternative that's "hard to get." That's the whole argument: semax fails pharmacokinetically, atomax fixes that, but good luck finding it.

To be clear about the transcript: the creator likely meant semax and a compound sometimes referred to as selank or a modified semax analog. The term "atomax" doesn't match any widely recognized pharmaceutical or research chemical name in the published literature, which creates an immediate credibility problem before we even get to the pharmacology.

Does the science back this up?

Partly, but not in the way the creator implies. Semax does have documented stability challenges, and some criticism of its real-world potency is grounded in legitimate pharmacokinetic concerns. The support stops there, because "atomax" as a named compound doesn't appear in peer-reviewed literature.

Semax is a synthetic heptapeptide analog of ACTH(4-7) developed in Russia. Studies like Dolotov et al. (2006, Annals of the New York Academy of Sciences) showed semax influences BDNF expression and has neuroprotective effects in animal models. Human clinical data is sparse. The stability concern is real: intranasal peptides face enzymatic degradation in nasal mucosa and serum, and brain bioavailability from nasal administration is genuinely hard to quantify. Eremin et al. (2005, Bulletin of Experimental Biology and Medicine) noted that semax's half-life is short, which limits sustained CNS effects. So the creator isn't making up the stability problem. But jumping from "semax degrades quickly" to "atomax is the solution" with no sourcing is a logical leap over a very wide gap.

What did they get wrong (or right)?

They got one thing right and several things wrong. Credit where it's due: the observation that semax has bioavailability limitations is not unreasonable, and it matches what the pharmacokinetic data suggests about short-chain peptide degradation.

What they got wrong is more significant. First, the claim that semax "lacks any sort of potency" once it crosses the blood-brain barrier misreads the actual critique. The issue is whether enough of it crosses at all, not that the molecule is inert once it does. BDNF upregulation data from animal studies suggests the molecule is pharmacologically active at the receptor level. Second, "atomax" is not a recognized research compound with published human or animal efficacy data. If the creator is referring to a modified semax analog, they needed to name it precisely, because unverified compound names in nootropic communities often refer to uncharacterized or mislabeled products. Third, the casual framing of "we've all tried" positions unregulated peptide self-experimentation as normal and low-risk, which is a framing problem.

What should you actually know?

Semax is not a well-studied compound by Western regulatory standards. Most human data comes from Russian clinical trials with limited independent replication. That doesn't make it useless, but it means the confidence interval on any claim about its potency, or lack thereof, is extremely wide.

The creator's alternative, "atomax," appears to have no verifiable identity in the scientific literature as of this writing. Compounds circulating in peptide communities under informal names may be research chemicals with unknown purity, stability, and dosing profiles. Buying something because a TikTok creator said it's "way more stable" with no cited source is not a pharmacology decision. It's a guess. If you're interested in cognitive peptides, the conversation worth having is with a licensed clinician who can review your actual health status, not a video where the compound being recommended can't be Googled back to a single peer-reviewed paper.